Hans Vitzthum
Overview
Explore the profile of Hans Vitzthum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2019 Jan;
176(1-2):404.
PMID: 30633907
No abstract available.
2.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2018 Nov;
175(4):998-1013.e20.
PMID: 30388456
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors...
3.
Jenkins R, Aref A, Lizotte P, Ivanova E, Stinson S, Zhou C, et al.
Cancer Discov
. 2017 Nov;
8(2):196-215.
PMID: 29101162
systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination...
4.
Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J, et al.
Nat Commun
. 2017 Oct;
8(1):1136.
PMID: 29070816
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain...